TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12531794
Drug: CNOP without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CNOP without G-CSF
Study: 8214043
Drug: Intralipid infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid infusion (10%; 30 ml/h)
Study: 8214043
Drug: Control (0.154
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0.154 mol/l NaCl)
Study: 3767596
Drug: Intravenous tryptophan
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tryptophan
Study: 17921388
Drug: Chilenje Baby
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chilenje Baby Mix (CBM); energy density: 68 kcal/100 g; n = 37
Study: 17921388
Drug: Chilenje Baby
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chilenje Baby Mix with alpha-amylase (CBMA); energy density: 106 kcal/100 g; n = 44
Study: 16150805
Drug: Trastuzumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab + chemotherapy (doxorubicin/cyclophosphamide or paclitaxel)
Study: 16150805
Drug: Trastuzumab-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab-based therapy
Study: 10653049
Drug: Salmeterol/fluticasone propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone propionate (50/500 microg) via a single Diskus inhaler (combination)
Study: 10653049
Drug: Salmeterol 50
Normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 50 microg and fluticasone propionate 500 microg administered via separate Diskus inhalers (concurrent)
Study: 16132802
Drug: Dietary supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplements
Study: 998551
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no dietary supplements)
Study: 19506005
Drug: Regular daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular daily activities
Study: 17045894
Drug: Polyunsaturated fatty
Normalized name: omega-3 polyunsaturated fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyunsaturated fatty acids (PUFA) 2 g/die
Study: 12740675
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg 6‐methylprednisolone acetate (6‐MPA)
Study: 11126257
Drug: Intralipid (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid (200 mg/ml) intravenously as a bolus injection (0.5 ml/kg) over 10 min and thereafter as a continuous intravenous infusion (90 ml/h) for 4 h combined with heparin (200 U/h)
Study: 11126257
Drug: Saline instead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline instead of Intralipid and heparin
Study: 18156922
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant treatment (control)
Study: 9133082
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with CMF and Tam
Study: 8329784
Drug: Four temazepam
Normalized name: Temazepam
DrugBank: Temazepam acetate (DB14671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Four temazepam 7.5‐mg capsules
Study: 8329784
Drug: One temazepam
Normalized name: Temazepam
DrugBank: Temazepam acetate (DB14671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One temazepam 30‐mg capsule
Study: 31775146
Drug: Transcorneal electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transcorneal electrical stimulation (TES) applied weekly for 6 months on 1 eye
Study: 22869834
Drug: Culturally tailored,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally tailored, family-centered behavioral intervention (Salud Con La Familia program) consisting of 12 weekly 90-minute sessions
Study: 18079068
Drug: Disulfiram (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disulfiram (250 mg/day)
Study: 12577162
Drug: Esketamine group
Normalized name: esketamine
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Esketamine group (n=21; induction with 0.5 mg/kg BW esketamine and 1.5 mg/kg BW methohexitone)
Study: 12577162
Drug: Sevoflurane group
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane group (n=21; induction with 1.5-2.0 mg/kg BW methohexitone)
Study: 12577162
Drug: Spinal anaesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anaesthesia group (n=22; 2.6-3.0 ml isobaric bupivacaine 0.5%)
Study: 10495859
Drug: Nickel sulfate
Normalized name: Nickel Sulfate
DrugBank: Nickel sulfate (DB14180)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nickel sulfate 5 mg (group A)
Study: 8904748
Drug: L-dopa 100
Normalized name: L-DOPA 100 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dopa 100 mg with benserazide 25 mg
Study: 7140494
Drug: Cimetidine plus
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine plus antacids as needed (prn)
Study: 22027945
Drug: Medroxyprogesterone (MPA)
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone (MPA) 10 mg/day for 14 days
Study: 11701427
Drug: CON (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: CON (saline infusion while breathing room air)
Study: 7831451
Drug: Imipramine hydrochloride
Normalized name: Imipramine Hydrochloride
DrugBank: Imipramine (DB00458)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imipramine hydrochloride (high-dose 3 mg/kg/day)
Study: 7831451
Drug: Imipramine hydrochloride
Normalized name: Imipramine Hydrochloride
DrugBank: Imipramine (DB00458)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imipramine hydrochloride (medium-dose 1.5 mg/kg/day)
Study: 2458035
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (human surfactant and control)
Study: 18556139
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose alcohol (.08%)
Study: 8879097
Drug: HAV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAV vaccine (1440 EL.U.)
Study: 8879097
Drug: HAV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAV vaccine plus YF vaccine
Study: 8879097
Drug: YF vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: YF vaccine
Study: 6434422
Drug: Nutritional support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional support with various infusion regimens
Study: 6434422
Drug: 3-methylhistidine excretion
Normalized name: SNAIL SECRETION FILTRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-methylhistidine excretion in urine
Study: 24976987
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care (individualized education and telephone counseling for 6 months)
Study: 9820261
Drug: Amitriptyline (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (75 mg/d)
Study: 20940647
Drug: Agonist/Antagonist (AA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agonist/Antagonist (AA) training group
Study: 14585520
Drug: Estradot (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradot (all doses)
Study: 10903016
Drug: Rocuronium 0.45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.45 mg kg(‐1)
Study: 10903016
Drug: Rocuronium 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.3 mg kg(‐1) followed by neostigmine 40 microg kg(‐1) and atropine 20 microg kg(‐1)
Study: 11253966
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B (100 mg/m2 cisplatin on day 1, 120 mg/m2 etoposide on days 1-3, 30 kU bleomycin on day 1, repeated every 21 days)
Study: 9633761
Drug: Prednisone plus
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone plus paracetamol
Study: 3664948
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: early instillation of adriamycin with oral administration of 5‐fluorouracil (200 mg/day)
Study: 3664948
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: delayed instillation of adriamycin (30 mg/30 ml)
Study: 3664948
Drug: Group D:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D: delayed instillation of adriamycin with oral administration of 5‐fluorouracil (200 mg/day)
Study: 29898707
Drug: Topical TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical TXA 1.0 g diluted in 50 ml normal saline injected into surgical site prior to tourniquet deflation
Study: 20572834
Drug: Mandibular implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular implant treatment with two implants and a new denture with magnet-, ball-socket, and bar-clip attachments
Study: 12746776
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment for HCV infection
Study: 11319683
Drug: ART plus
Normalized name: Tri-Heart Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ART plus IL‐2 (12 million IU by continuous intravenous infusion, followed by 7.5 MIU twice a day, sc, every 8 weeks)
Study: 11319683
Drug: ART plus
Normalized name: Tri-Heart Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ART plus IL‐2 (7.5 MIU twice a day, sc, every 8 weeks)
Study: 31153990
Drug: Etizolam 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etizolam 0.25 mg
Study: 31153990
Drug: Etizolam 1.00
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etizolam 1.00 mg
Study: 25883952
Drug: High intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intensity laser therapy (10 sessions)
Study: 25883952
Drug: Ultrasound therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound therapy (10 sessions)
Study: 25883952
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy and isometric lumbar exercises (10 days)
Study: 18049092
Drug: N-butylscopolamine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-butylscopolamine (20 mg intravenously)
Study: 15816569
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of cisatracurium (0.1 mg kg(‐1) at induction followed by continuous infusion) in Group 2
Study: 10547208
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with insulin and sulphonylureas (glibenclamide 10.5 mg daily)
Study: 8638193
Drug: Newer steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newer steroid preparations (investigational)
Study: 8638193
Drug: Immunosuppressive agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive agents (6-mercaptopurine, azathioprine, methotrexate)
Study: 27560995
Drug: Daily motivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily motivation and self-efficacy assessments via ecological momentary assessment (EMA)
Study: 19786664
Drug: R-CHOP treatment
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP treatment (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone)
Study: 17715638
Drug: Spironolactone 100‐200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 100‐200 mg/d and furosemide 20‐40 mg/d
Study: 8152445
Drug: Propranolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (mean dose 212 +/- 68 mg per day)
Study: 2008130
Drug: Terodiline (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terodiline (25 mg daily)
Study: 21741829
Drug: Continuation/restart of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation/restart of anti-HER2 treatment (trastuzumab or lapatinib) after 2nd progression
Study: 21741829
Drug: No anti-HER2
Normalized name: NO
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No anti-HER2 treatment after 2nd progression
Study: 16500339
Drug: Mechanical bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechanical bowel preparation (MBP) with 90 mL of oral sodium phosphate (NaP)
Study: 6087702
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition for 4 weeks
Study: 6087702
Drug: Self-regulated oral
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-regulated oral diet (control group)
Study: 28581356
Drug: Pertuzumab added
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pertuzumab added to standard adjuvant chemotherapy plus 1 year of trastuzumab
Study: 28581356
Drug: Placebo added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo added to standard adjuvant chemotherapy plus 1 year of trastuzumab
Study: 26406018
Drug: Mtwo Ni‐Ti
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mtwo Ni‐Ti rotary instrument combined with ultrasonic irrigation of a 2.5% NaOCl solution (Group A)
Study: 26406018
Drug: Mtwo Ni‐Ti
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mtwo Ni‐Ti rotary instrument combined with ultrasonic irrigation of an active silver ion antibacterial solution (Group B)
Study: 26406018
Drug: Syringe irrigation
Normalized name: Irrigation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syringe irrigation of a 2.5% NaOCl solution (Group C)
Study: 20694469
Drug: Sulfadoxine-pyrimethamine (SP)
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine-pyrimethamine (SP) treatment, 25 mg/kg sulfadoxine and 1.25 mg/kg pyrimethamine, administered once in September, October, and November (3 doses total)
Study: 11575684
Drug: All Stars
Normalized name: Star Anise Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: All Stars program administered by specialists
Study: 7997085
Drug: Interferon alfa-2A
Normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa-2A treatment
Study: 17182361
Drug: Iscador therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iscador therapy (mistletoe preparation)
Study: 9100997
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 50 mg bromfenac
Study: 8263444
Drug: Injections given
Normalized name: TITANIUM DIOXIDE 7.75 g in 100 mL / ZINC OXIDE 10 g in 100 mL TOPICAL CREAM [Give Me Shade Sunscreen Broad Spectrum SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injections given outside the mental foramen
Study: 18564231
Drug: fesoterodine 8
Normalized name: fesoterodine 8 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: fesoterodine 8 mg
Study: 17651893
Drug: tolterodine ER
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolterodine ER 4 mg
Study: 26037427
Drug: Protocol-based early
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol-based early goal-directed therapy (EGDT)
Study: 24145346
Drug: Pemetrexed (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (500 mg/m²) plus carboplatin (AUC 6) plus bevacizumab (15 mg/kg) followed by maintenance pemetrexed plus bevacizumab (PemCBev)
Study: 17223865
Drug: Rambazole, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rambazole, 1 mg, once daily for 8 weeks
Study: 12600850
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil meal (80 g)
Study: 26359750
Drug: Graded Exercise
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graded Exercise Therapy (GET) plus Specialist Medical Care (SMC)
Study: 26359750
Drug: Adaptive Pacing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive Pacing Therapy (APT) plus Specialist Medical Care (SMC)
Study: 22108275
Drug: Maximal tolerable
Normalized name: Spirulina maxima preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal tolerable dose of valsartan (up to 320 mg/day)
Study: 22108275
Drug: Usual dose
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual dose of valsartan (80 mg/day)
Study: 15121488
Drug: Modafinil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (200 mg single dose)
Study: 16581685
Drug: Red LED
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red LED therapy (20 min, 96 J/cm2, 633 nm)
Study: 14529770
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with cisplatin (20 mg/m(2)) and twice-daily accelerated irradiation (1.8 Gy to pelvis, 1.6 Gy to tumor)
Study: 14529770
Drug: Induction and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction and consolidation chemotherapy
Study: 1457360
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (CAFt: cyclophosphamide 500 mg m‐2 + doxorubicin 40 mg/m‐2 + ftorafur 20 mg kg‐1 orally day 1‐14)
Study: 6373547
Drug: Propranolol (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (twice daily at doses that reduced resting heart rate by 25%)
Study: 17065180
Drug: Trimetazidine (TMZ)
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (TMZ) 20 mg thrice daily for 72 hours starting 48 hours before the procedure
Study: 17065180
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (isotonic saline infusion only)
Study: 6111742
Drug: Placebo medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo medication
Study: 11313831
Drug: IC351 (Cialis)
Normalized name: Cialis
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IC351 (Cialis) 2 mg
Study: 11313831
Drug: IC351 (Cialis)
Normalized name: Cialis
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IC351 (Cialis) 5 mg
Study: 11313831
Drug: IC351 (Cialis)
Normalized name: Cialis
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IC351 (Cialis) 10 mg
Study: 11313831
Drug: IC351 (Cialis)
Normalized name: Cialis
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IC351 (Cialis) 25 mg
Study: 2128879
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clomiphene citrate and bromocriptine
Study: 27159505
Drug: Rifampin (approximately
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (approximately 10 mg/kg) plus ethambutol
Study: 19367153
Drug: Extended-release carbamazepine
Normalized name: carbamazepine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release carbamazepine capsules (ERCC)
Study: 19367153
Drug: Immediate-release carbamazepine
Normalized name: carbamazepine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release carbamazepine (IR)
Study: 12114886
Drug: Duloxetine 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 80 mg/day
Study: 14584381
Drug: Sulfadoxine-pyrimethamine (SP)
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine-pyrimethamine (SP) combined with a single dose of artesunate (AS)
Study: 1759572
Drug: Betamethasone (BM)
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone (BM) therapy
Study: 29510352
Drug: affron® (saffron
Approvals — FDA: no, EMA: no, PMDA: no
Description: affron® (saffron extract), 14 mg b.i.d
Study: 16364834
Drug: Melatonin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (3 mg, slow-release pill, administered 1 hour before bed for 3 weeks)
Study: 16364834
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered for 3 weeks)
Study: 12055812
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of albendazole and ivermectin
Study: 9872876
Drug: Migraine with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Migraine with coexistent oral contraceptive use, high blood pressure, or smoking
Study: 2325960
Drug: Hourly oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hourly oxytocin infusion protocol
Study: 2325960
Drug: Quarter-hourly oxytocin
Normalized name: Quarter Mate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quarter-hourly oxytocin infusion protocol
Study: 7404129
Drug: Gut hormones
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gut hormones (gastrin, secretin, CCK-PK)
Study: 6363382
Drug: tobramycin +
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: tobramycin + penicillin G
Study: 29680656
Drug: Candida tropicalis
Normalized name: CANDIDA TROPICALIS
DrugBank: Candida tropicalis (DB10807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candida tropicalis added at 1 g/calf per day (CT)
Study: 29680656
Drug: Mulberry leaf
Normalized name: MULBERRY
DrugBank: Broussonetia papyrifera pollen (DB10736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mulberry leaf flavonoids added at 3 g/calf per day (MLF)
Study: 20456336
Drug: Risedronate 35
Normalized name: risedronate 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 35 mg/week
Study: 10730559
Drug: Mesalazine enema
Normalized name: mesalamine Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine enema (2 g/60 ml twice a day)
Study: 6165750
Drug: Chamber A
Normalized name: Dual Chamber Automix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chamber A (1000 PNU/ml ragweed extract)
Study: 6165750
Drug: Chamber C
Normalized name: Flexichamber Child Mask (Large)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chamber C (1000 PNU/ml ragweed and 50 ng histamine)
Study: 30177585
Drug: Pemetrexed monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed monotherapy (P)
Study: 26742388
Drug: Non-restricted medication
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-restricted medication
Study: 18430685
Drug: Targeted implanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted implanted cortical electrical stimulation of the motor cortex with upper limb rehabilitation therapy